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Abstract
Objective: To evaluate effectiveness and safety of tocilizumab (TCZ) in biologic-naive Japanese
patients with rheumatoid arthritis (RA) in real-world settings, and to analyze the relationship
between disease duration and clinical outcomes.
Methods: The FIRST Bio study was a postmarketing surveillance study of intravenous TCZ in
biologics-naive patients who had a prior inadequate response or were intolerant to 1
conventional synthetic disease-modifying antirheumatic drug (csDMARD). Effectiveness, safety,
and concomitant csDMARD administration were assessed.
Results: Of the 839 patients analyzed, 72.3% completed 52 weeks of treatment. The Clinical
Disease Activity Index (CDAI) remission rate at week 52 was 36.8%. Contributing factors for
CDAI remission were younger age, early disease stage, and no comorbidities. Health
Assessment Questionnaire Disability Index 0.5 was achieved in 65.1% of patients, and was
significantly associated with disease duration. Discontinuation of concomitant methotrexate
(MTX) and glucocorticoids (GCs) was possible in 19.3% and 34.1% of patients, respectively,
without decreasing remission rate. The incidence (events/100 patient-years) of serious adverse
events was 18.09, the most common being infection.
Conclusion: These data validate the importance of TCZ treatment in the early stages of RA in
biologic-naive patients to achieve increased effectiveness. The safety profile of TCZ was
reconfirmed. Furthermore, TCZ therapy may allow discontinuation of concomitant MTX and
GCs without affecting remission.
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Introduction
Phase III clinical studies of the recombinant humanized anti-
human interleukin-6 (IL-6) receptor monoclonal antibody tocili-
zumab (TCZ) demonstrated improved disease activity and
inhibition of joint destruction in patients with rheumatoid arthritis
(RA) with or without concomitant use of conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs) including
methotrexate (MTX) [1–7]. TCZ has since received marketing
approval as an antirheumatic agent in more than 100 countries,
including Japan in 2008, the European Union in 2009, and the
United States in 2010. Upon TCZ approval, its safety and
effectiveness in the Japanese real-world clinical setting were
evaluated in the all-patient postmarketing surveillance (PMS)
program in patients with RA, with a 28-week follow-up period in
7901 patients (PMS7901) [8]. A subsequent 3-year follow-up
PMS evaluated the long-term safety in 5573 patients [8,9]. A
benefit-risk balance analysis of TCZ was performed with the
28-week PMS program to characterize which patients obtained the
best clinical outcomes with TCZ [8]. The benefit-risk balance
revealed that patients categorized as having a higher predicted
probability of achieving American College of Rheumatology and
European League Against Rheumatism (ACR/EULAR) Boolean-
based remission criteria and a lower predicted probability of
developing a serious infection (SI) after receiving TCZ were more
likely to be younger and biologics naive, with a shorter disease
duration and an earlier Steinbrocker disease stage and functional
class. These patients were also less likely to have comorbidities
and concomitant use of glucocorticoids (GCs). These results
suggested that early initiation of TCZ treatment in patients with
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less advanced RA may result in the most beneficial outcomes for
these patients.
In this study, we aimed to evaluate the effectiveness and safety
of TCZ in biologics-naive patients with RA over a 52-week period
in real-world clinical settings in Japan. In addition, we examined
the possibility of decreasing or discontinuing concomitant MTX
and GC dosage during treatment with TCZ.
Methods
Patients
Biologics-naive patients with RA who met the ACR/EULAR 2010
classification criteria for RA and had an inadequate response or
were intolerant to one or more csDMARDs were enrolled [10].
Patients were enrolled in this study prospectively. In accordance
with the Japan College of Rheumatology Guidelines for receiving
TCZ, it was recommended that patients meet all the following
criteria before starting TCZ treatment: 6 tender joints (68-joint
count),6 swollen joints (66-joint count), erythrocyte
sedimentation rate (ESR) 28mm/h or C-reactive protein
(CRP) 2.0mg/dl, white blood cell count 4000/mm3, lympho-
cyte count 1000/mm3, and serum b-D-glucan–negative. Before
TCZ treatment was initiated, all patients were required to undergo
screening for tuberculosis [11].
Protocol
The FIRST Bio study is a single-arm observational PMS study that
began in January 2012. Patient registration, which occurred before
starting TCZ treatment, was centrally controlled. Patients received
TCZ 8mg/kg intravenously once every 4 weeks. During the TCZ
treatment period, there were no restrictions on the use of
concomitant csDMARDs such as MTX or GCs. Data were
collected using case report forms, and patients were evaluated for
52 weeks after TCZ was initiated or within 4 weeks of the last
TCZ infusion. Effectiveness was assessed at weeks 0, 12, 24, 36,
and 52. Disease activity was measured by the Clinical Disease
Activity Index (CDAI) and by the Disease Activity Score based on
28-joint-ESR (DAS28-ESR) [12–14]. The rate of remission was
assessed using CDAI (CDAI 2.8), DAS28-ESR (DAS28-ESR
52.6), and ACR/EULAR Boolean-based remission criteria [15].
Because it may be possible to underestimate disease activity using
composite measures such as CRP that include acute phase
reactants associated with IL-6 CDAI, which does not include the
acute phase reaction as estimate factor, was mainly used to analyze
the effectiveness of TCZ in improving RA signs and symptoms in
this study. The activity of daily life, an aspect of quality of life,
was evaluated by the Health Assessment Questionnaire Disability
Index (HAQ-DI) [16,17]. The frequency of achieving HAQ-DI
0.5 was also assessed, which signifies normal physical function.
Doses of concomitant MTX and GCs were measured at weeks 0,
12, 24, 36, and 52 [18]. All adverse events (AEs) that occurred
during the 52 weeks after the first TCZ infusion were included in
the safety analysis.
Statistical analysis
All AEs and serious AEs (SAEs) were coded using the Medical
Dictionary for Regulatory Activities (MedDRA, vol. 16.1). The
last-observation-carried-forward method and non-responder
imputation method were utilized to analyze outcomes from
baseline to week 52. Patients without either baseline or last
observation point values of disease activities were excluded from
each effectiveness analysis model. Paired t-tests were used to
detect differences between the mean CDAI, DAS28-ESR, HAQ-
DI, MTX dosage, and oral GC dosage from baseline to week 52.
Chi-square tests were used to detect differences between groups of
patients using frequency data. Cochran–Armitage tests were used
to detect the difference between the patients in the respective
disease duration subgroups. A Kaplan–Meier plot was used to
display time to withdrawal in patients who received TCZ and who
did not change their hospital during the study period. Patients were
stratified by baseline characteristics, and clinical and functional
outcomes were compared. Statistical analysis of patient back-
ground was nominally done to determine the effect of patient
characteristics on the achievement of CDAI remission. A p value
50.05 was considered to be statistically significant.
Results
Patient demographics
In total, 298 sites participated in this study, and 850 patients were
enrolled. Eleven patients were excluded from the safety analysis
population due to no collection of case report forms (seven
patients), and retroactive enrollment (four patients); 839 patients
were included in the final analysis (Supplementary Figure 1). The
cumulative exposure to TCZ was 718.4 patient-years (PY). Patient
characteristics are described in Table 1. The median age (min–
max) was 62.0 (15–90) years with a median (min–max) disease
duration of 3.46 (0.0–54.4) years. A total of 319 patients (38.0%)
had a history of 1 previous comorbidity, the most common being
appendicitis in 23 patients (2.7%), uterine leiomyoma and
interstitial lung disease, each with 18 patients (2.1%). A total of
483 patients (57.6%) had 1 current comorbidity, with the most
common being hypertension in 154 patients (18.4%). A total of
680 patients (81.0%) and 506 patients (60.3%) were classified as
Steinbrocker functional class 1 or 2 and Steinbrocker radiographic
stages I and II, respectively. Concomitant csDMARDs and MTX
were administered in 81.2% and 62.7% of patients, respectively.
Of the 805 patients who were treated with TCZ and did not
change their hospital, 692 (86.0%) and 582 (72.3%) were still
receiving TCZ at weeks 24 and 52, respectively (Supplementary
Figure 2). Of the 223 patients who discontinued TCZ in the safety
analysis population (n¼ 839), the primary reasons were onset of
AEs in 74 patients (33.2%), insufficient effectiveness in 47
patients (21.1%), request from patients in 41 cases (18.4%), and 18
patients discontinued study visits (8.1%).
Effectiveness
There was a significant improvement in mean (SD) CDAI from
baseline to week 52 (23.3 [11.8] versus 6.6 [7.5]; p50.0001)
(Figure 1A). The proportion of patients who achieved CDAI
remission (CDAI 2.8) was 36.8%; low disease activity (CDAI
42.8 to 10) was 43.0%; moderate disease activity (CDAI410 to
22) was 14.8%; and high disease activity (CDAI422) was 5.4%
at week 52 (Figure 1B). Of the patients who achieved CDAI
remission at week 24, 73.7% sustained this remission at week 52.
When stratified by disease duration, there was a significant
difference in the proportion of patients who achieved CDAI
remission at week 24 across disease duration subgroups
(p50.0001; Figure 1C): patients with disease duration52 years
(40.2%), 2 to55 years (29.6%), 5 to510 years (29.9%), and
10 years (20.5%). However, the rate of CDAI remission in
patients with disease duration 10 years increased after 24 weeks,
and there was no significant difference in the proportion of
patients who achieved CDAI remission at week 52 across disease
duration subgroups (p¼ 0.0601; Figure 1C): patients with disease
duration52 years (42.9%),  2 to55 years (33.6%),5 to510
years (35.6%), and 10 years (33.5%). This trend was confirmed
when assessed by non-responder imputation methods. There was a
significant difference in CDAI remission rates at week
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24 in patients with disease duration52 years, 2 to55 years, 5
to510 years, and 10 years (37.5%, 28.0%, 28.8%, and 19.9%,
respectively; p¼ 0.0001); however, a significant difference in the
rates of CDAI remission was not observed at week 52 (36.7%,
25.6%, 31.4%, and 27.8%, respectively; p¼ 0.0918).
The rate of CDAI remission was significantly higher in patients
who were younger and had an earlier Steinbrocker stage and
better functional class, and a lower HAQ-DI score, with no
concomitant use of GCs and non-steroidal anti-inflammatory drugs,
and had no comorbidities such as respiratory disorders (Table 2).
The CDAI remission rate at week 52 was not affected by the
presence or absence of concomitant MTX, concomitant MTX dose,
or the presence or absence of rheumatoid factor (Table 2).
DAS28-ESR (mean [SD]) also significantly improved from
baseline to week 52 (5.2 [1.2] versus 2.1 [1.3]; p50.0001)
(Figure 2A). The proportion of patients who achieved DAS28-
ESR remission (DAS28-ESR 52.6) was 68.5%; low disease
activity (DAS28 2.6 to53.2) was 14.0%; moderate disease activ-
ity (DAS28 3.2 to 5.1) was 15.5%; and high disease activity
(DAS2845.1) was 2.0% (Figure 2B). The proportion of patients
who achieved ACR/EULAR Boolean-based remission criteria was
33.1% at week 52 (Figure 2C). Of the patients who achieved
DAS28-ESR or ACR/EULAR Boolean-based remission criteria at
week 24, 90.0% and 74.6% sustained this remission at week 52,
respectively.
Quality of life, measured by HAQ-DI (mean [SD]), signifi-
cantly improved from baseline to week 52 (1.0 [0.8] versus 0.5
[0.7]; p50.0001; Figure 3A), with 65.1% of patients demonstrat-
ing normal physical function (HAQ-DI score 0.5) at week 52
(Figure 3B). Of the patients who achieved an HAQ-DI score 0.5
at week 24, 95.6% sustained an HAQ-DI score 0.5 at week 52.
When stratified by disease duration, there was a statistically
significant difference in the proportion of patients whose HAQ-DI
score was 0.5 across patients with disease duration52 years, 2
to55 years,  5 to510 years, and 10 years from weeks 12 to
52, with a gradual increase in the difference during the 52 weeks
of TCZ treatment, especially between the52 year and 10 year
disease duration groups (Figure 3C).
Concomitant drugs
Among patients receiving concomitant MTX, the mean dose of
MTX decreased from 9.1mg/week at baseline to 6.4mg/week at
week 52 (p50.0001; Figure 4A); 72 patients (19.3%) discontinued
MTX. Oral GCs were administered in 440 patients (one patient
with unknown dose) (52.4%) at baseline and the mean GC dose
(prednisolone-equivalent) of these patients was reduced from
5.4mg/d at baseline to 2.6mg/d at week 52 (p50.0001;
Figure 4B). GC administration was discontinued in 102 (34.1%)
patients. CDAI (mean [SD]) in patients who discontinued
concomitant MTX or GCs significantly improved from baseline
to week 52 (24.8 [15.2] to 5.1 [5.4], p50.0001, and 22.1 [9.9] to
5.1 [4.9], p50.0001, respectively). The rate of CDAI remission
did not decrease by week 52 in patients who discontinued MTX or
GC administration (Supplementary Figure 3).
Safety
Overall, during the 52-week observation period there were 544
AEs in 308 patients (36.71%, 75.72 events/100 PY) and 130
SAEs in 101 patients (12.03%, 18.09 events/100 PY) (Table 3).
The most common AEs and SAEs were infections (128 AEs in
103 patients [12.27%], 17.81 AEs/100 PY), with 42 SIs
occurring in 38 patients (4.52%, 5.84 SAEs/100 PY). The
incidence rate of SI was not significantly associated with age
(4.16% in patients565 years of age, and 5.07% in patients 65
years of age, [p¼ 0.536]). Pneumonia was the most frequent SI
(seven events in seven patients [0.83%], 0.97 events/100 PY).
Table 1. Characteristics of patients with RA participating in the FIRST
Bio study.
Characteristics
Patients receiving TCZ
(N¼ 839)
Total PY 718.4
Female, n (%) 646 (77.0)
Age, years, mean (SD) 59.6 (13.5)
Median, range 62 (15–90)
 65, n (%) 335 (39.9)
Body weight, kg, mean (SD) 54.4 (10.7)
Body weight540 kg, n (%) 35 (4.2)
Disease duration, years, mean (SD) 7.5 (8.9)
Median, range 3.5 (0.0–54.4)
History of comorbidities, n (%) 319 (38.0)
Appendicitis 23 (2.7)
Uterine leiomyoma 18 (2.1)
Interstitial lung disease 18 (2.1)
Tuberculosis 16 (1.9)
Pneumonia 13 (1.5)
Gastric ulcer 13 (1.5)
Breast cancer 12 (1.4)
Comorbidities, n (%) 483 (57.6)
Hypertension 154 (18.4)
Osteoporosis 153 (18.2)
Hyperlipidemia 91 (10.8)
Diabetes mellitus 70 (8.3)
Interstitial lung disease 52 (6.2)
Gastritis 48 (5.7)
Gastroesophageal reflux disease 34 (4.1)
Anemia 27 (3.2)
Clinical characteristics
Steinbrocker radiographic stage, n (%)
I 216 (25.7)
II 290 (34.6)
III 184 (21.9)
IV 149 (17.8)
Steinbrocker functional class, n (%)
1 156 (18.6)
2 524 (62.5)
3 145 (17.3)
4 14 (1.7)
RF +, (%) 64.5
Baseline DAS28-ESR, mean (SD) 5.2 (1.2)
Baseline CDAI, mean (SD) 23.3 (11.8)
Baseline HAQ-DI, mean (SD) 1.0 (0.8)
Baseline CRP, mg/dl, mean (SD) 2.4 (2.8)
Baseline ESR, mm/h, mean (SD) 46.2 (30.1)
Concomitant csDMARD use, n (%)a 681 (81.2)
Concomitant MTX, n (%)a 526 (62.7)
MTX dose, mg/week, mean (SD) 9.1 (3.9)
MTX dose, mg/week, min–max 2.0–64.0b
Concomitant oral corticosteroid use, n (%)a 440 (52.4)
Corticosteroid dose, mg/d, mean (SD) 5.4 (3.2)
Corticosteroid dose, mg/d, min–max 0.5–25.0
aConcomitant use at baseline.
bOne patient received 64.0mg/week of MTX for 1 week due to incorrect
administration before starting TCZ treatment. After that, the patient
received 4mg/week of MTX.
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein;
csDMARD, conventional synthetic disease-modifying antirheumatic
drug; DAS28-ESR, Disease Activity Score based on 28-joint-erythro-
cyte sedimentation rate; ESR, erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire Disability Index; MTX, methotrexate;
PY, patient-years; RA, rheumatoid arthritis; RF, rheumatoid factor; SD,
standard deviation; TCZ, tocilizumab.
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Six patients developed malignancies (0.71%, 0.83 events/100
PY). Six deaths were reported, due to interstitial lung disease in
one patient, gastric cancer in one patient, hemorrhagic shock in
one patient that occurred after a liver biopsy to investigate the
cause of hepatic dysfunction during TCZ treatment, ruptured
aortic aneurysm/sepsis in one patient, and with an unknown
cause in two patients. Gastrointestinal perforations occurred in
two patients (0.23%, 0.27 events/100 PY); of these, one patient
had a history of intestinal inflammation. No cases of anaphyl-
axis were reported. Serious hepatobiliary disorders occurred in
10 patients (1.19%, 1.53 events/100 PY). Interstitial lung
diseases occurred in nine patients (1.07%, 1.25 events/100
PY); of these, one patient had a concurrent medical history of
interstitial lung disease at baseline. A serious cardiovascular
disorder (angina pectoris) occurred in one patient (0.11%, 0.13
events/100 PY).
Discussion
This study demonstrated that TCZ treatment in the early stages of
RA in biologics-naive patients achieves better effectiveness and
control of RA. Moreover, it was shown that TCZ therapy may
allow discontinuation of concomitant MTX and GCs without
affecting remission.
The benefit-risk balance analysis of PMS7901 revealed that
patients with a higher probability of remission and lower
probability of developing SI were more likely to be biologics
naive, have had RA for a shorter duration, and have less
advanced disease stage and class [8]. Patients in the FIRST
Bio study were biologics naive with shorter median disease
duration than the population studied in PMS7901 (7.5 years
versus 10.4 years, respectively) and had less advanced
Steinbrocker functional class than those in PMS7901 (81.0%
versus 73.8% of patients with class 1 or 2, respectively) [9].
Median age was similar in the FIRST Bio study and PMS7901
(62.0 and 60.0 years, respectively), and more than half (57.6%)
of the patients had a comorbidity in the FIRST Bio study.
Although the FIRST Bio study and PMS7901 were single-arm
observational studies and not comparative studies due to
differences in the patient population, observation period, and
clinical experience, the ACR/EULAR Boolean-based remission
rate at week 24 in the FIRST Bio study (27.7%) was higher
than the result from PMS7901 at week 28 (15.1%). Moreover,
the DAS28-ESR remission rate at week 24 in the FIRST Bio
Figure 1. Effect of TCZ over time on (A) mean CDAI, (B) categorization of CDAI disease activity, and (C) achievement of CDAI remission (CDAI
2.8) by disease duration subgroups. CDAI, Clinical Disease Activity Index; TCZ, tocilizumab.
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study (64.9%) was numerically higher than in PMS7901 at
week 28 (47.6%). A strength of the present study comes from
the measurement of the CDAI remission rate (36.8% at 52
weeks), which was not reported in PMS7901. Stratification of
the effectiveness results in this study by patient characteristics
revealed that younger age, early disease stage and class, and
low HAQ-DI score were associated with higher rates of CDAI
remission, confirming the benefit-risk balance analysis of
PMS7901, which showed that patients with a high probability
of remission and low probability of developing SI were more
likely to be biologics naive, younger, and have early and less
advanced RA. Future studies with multivariate analysis are
needed to verify these findings.
The effectiveness of TCZ was evaluated in groups of patients
stratified by disease duration. In patients with disease duration
10 years, the CDAI remission rate continuously improved after
week 24, and by 52 weeks, there was no statistically significant
difference between the proportion of patients achieving CDAI
Table 2. Effect of patient characteristics on the development of CDAI remission.a
Patients receiving TCZ
(N¼ 722)
Patients in remission
(N¼ 266)
Remission rate, %
(36.8%)
p
Age, years
515 0 0 – *
15 to565 435 173 39.8 0.0446
65 287 93 32.4
Steinbrocker radiographic stage
I 180 84 46.7 ***
II 254 100 39.4 0.0005
III 159 42 26.4
IV 129 40 31.0
Steinbrocker functional class
1 138 66 47.8 ***
2 450 169 37.6 0.0003
3 123 29 23.6
4 11 2 18.2
Baseline DAS28
5.1 340 138 40.6 NS
45.1 349 120 34.4 0.0925
Unknown 33 8 24.2
Baseline HAQ-DI score
1 326 127 39.0 *
41 to 2 170 55 32.4 0.0184
42 to 3 58 12 20.7
Unknown 168 72 42.9
Baseline RF
Positive 483 176 36.4 NS
Negative 103 44 42.7 0.2321
Unknown 136 46 33.8
Medication at baseline
MTX, no 134 43 32.1 NS
MTX, yes 460 177 38.5 0.1777
Dose, mg/week
40 to58 121 46 38.0 NS
8 339 131 38.6 0.9032
Glucocorticoids, no 346 145 41.9 **
Glucocorticoids, yes 376 121 32.2 0.0067
Dose, mg/d
40 to52.5 43 14 32.6 NS
2.5 to55.0 106 33 31.1 0.8077
5.0 to57.5 137 49 35.8
7.5 to510.0 39 12 30.8
10.0 49 13 26.5
Unknown 2 0 0
NSAIDS, no 395 160 40.5 *
NSAIDs, yes 327 106 32.4 0.0248
Comorbidity, no 313 147 47.0 ***
Comorbidity, yes 409 119 29.1 50.0001
Respiratory disease, no 641 246 38.4 *
Respiratory disease, yes 81 20 24.7 0.0161
NS: p 0.05; *p50.05; **p50.01; ***p50.001.
aThe following patient characteristics were analyzed: sex, age (years), body weight (kg), disease duration (years), disease
stage classified by Steinbrocker, function classified by Steinbrocker, baseline DAS28, baseline HAQ-DI score, baseline
RF, medication history of conventional synthetic DMARDs, number of conventional synthetic DMARDs, concomitant
use of MTX, dose of MTX (mg/week) at baseline, concomitant use of glucocorticoids, dose of glucocorticoids (mg/d) at
baseline, concomitant use of NSAIDs, medical history of infection, comorbidity of respiratory disease, hepatic function
disorder, renal disease, and diabetes mellitus. CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic
disease-modifying antirheumatic drugs; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment
Questionnaire Disability Index; MTX, methotrexate; NS, not significant; NSAID, non-steroidal anti-inflammatory drug;
RF, rheumatoid factor; TCZ, tocilizumab.
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remission in the 10-year and52-year disease duration groups.
However, the proportion of patients with HAQ-DI score 0.5 at
both weeks 24 and 52 was significantly higher among patients
with disease duration52 years than those with disease duration
10 years. These data further suggest that aggressive therapy with
TCZ for patients with RA in the early stage of disease
development is more beneficial than at later stages. Notably,
these results imply that the signs and symptoms of RA in patients
with established RA may be well controlled by long-term TCZ
treatment.
The presence of RF was not associated with CDAI remission
rates during TCZ treatment, and a similar result was reported in a
previous study with TCZ [19]. Conflicting data exist for TNF
inhibitor therapy, with some studies suggesting that the status of
RF is associated with a clinical response and some studies
reporting no such correlation [20–26]. In the case of abatacept,
efficacy was reported to be lower in patients who were RF
negative than those who were RF positive [27]. The results of this
study suggest that RF status is not a factor that affects the ability of
TCZ to improve disease activity.
In this study, the concomitant medication of MTX during TCZ
treatment did not affect remission rates. In contrast, other biologics
with different mechanisms of action are reported to be more
effective in treating RA when administered with concomitant
MTX [19,28–34]. Further studies are needed to determine the
mechanisms that account for this difference.
Interestingly, concomitant MTX and GC doses were signifi-
cantly reduced during TCZ treatment without disease flare in this
study. The risk of MTX-associated lymphoproliferative disorders
(MTX-LPD) has been reported during long-term usage of MTX,
which is widely used for the treatment of RA [35]. Thus, if MTX
can be tapered or discontinued after improving disease activity
with TCZ treatment, patients may have the benefit of reduced risk
of MTX-LPD. In the case of TNF inhibitor therapy, literature
reporting that concomitant MTX could be reduced without
impacting disease activity is limited [36–38]. Long-term use of
GCs is well known to be associated with various adverse drug
reactions, and the guidelines recommend tapering GC dose after
improvement of disease activity [39–41]. Prospective studies are
necessary to evaluate safe and effective methods for discontinuing
MTX and/or GCs in patients with RA receiving TCZ.
The incidence rates of total AEs and SAEs were numerically
lower in the FIRST Bio study than PMS7901 (75.72 events/100
PY versus 168.59 events/100 PY for AEs, and 18.09 events/100
PY versus 27.40 events/100 PY for SAEs, respectively) [8].
Further, the incidence rates of total and SIs were numerically
Figure 2. Effect of TCZ over time on (A) mean DAS28-ESR, (B) categorization of DAS28-ESR disease activity, and (C) ACR/EULAR Boolean-based
remission rate. DAS28-ESR, Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; TCZ, tocilizumab.
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Figure 3. Effect of TCZ over time on (A) mean HAQ-DI, (B) achievement of HAQ-DI 0.5, and (C) achievement of HAQ-DI 0.5 by disease duration
subgroups. DAS28-ESR, Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; TCZ, tocilizumab.
Figure 4. Change in concomitant (A) MTX and (B) GC (oral) dose during TCZ treatment. GC, glucocorticoid; MTX, methotrexate; TCZ, tocilizumab.
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lower in FIRST Bio study than PMS7901 (17.81 events/100 PY
versus 27.87 events/100 PY in AEs, and 5.84 events/100 PY
versus 8.61 events/100 PY in SAEs, respectively) [8]. In addition,
the incidence rate of SIs in this study was similar to the rate in the
long-term clinical studies of TCZ in Japan (5.84 events/100 PY
versus 6.22 events/100 PY, respectively), which were also carried
out in a high number of biologic-naive patients [42]; therefore, the
FIRST Bio study validates the safety profile of TCZ in biologics-
naive patients. Importantly, no new safety signals were identified
in the present study.
In conclusion, these results highlight the importance of TCZ
treatment in the early stages of RA in biologics-naive patients in
achieving better control of signs and symptoms as well as safety.
Furthermore, tapering of MTX or GC dose during concomitant
therapy with TCZ was possible with the maintenance of remission
in patients with RA.
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